However, KRAS and BRAF mutations are prevalent in CRC, leading to the aberrant activation of the MAPK pathway and rendering approximately 60% of CRC patients unresponsive to cetuximab therapy [14]. The gene discussed is KRAS; the disease is colorectal carcinoma.